Can Adderall Cause Psychosis? What the Studies and the FDA Label Show

The FDA label for Adderall XR states that stimulants, at the recommended dosage, may cause psychotic or manic symptoms in patients without a prior history of psychotic illness or mania.² Psychosis was uncommon in the largest study cited here: among 221,846 patients aged 13 to 25 with ADHD who started a prescription stimulant, new-onset psychosis occurred in approximately 1 in 660.¹

In that study, an episode of psychosis occurred in 0.21% of patients who started amphetamine and 0.10% of patients who started methylphenidate.¹ The abstract reports amphetamine and methylphenidate as drug classes and names no products, so these figures aren't specific to Adderall. Adderall XR contains mixed amphetamine salts, Vyvanse (lisdexamfetamine) is a prodrug of d-amphetamine, and Ritalin and Concerta contain methylphenidate.^{2, 3, 4, 5}

New hallucinations, delusional thinking, or other psychotic symptoms on a stimulant mean contacting the prescriber right away or going to urgent or emergency care. Decisions about the medication are made with the prescriber.

How common psychosis is on a prescription stimulant

The 2019 study used two commercial insurance claims databases and followed patients 13 to 25 years old with an ADHD diagnosis who started methylphenidate or amphetamine between 2004 and 2015. An episode was counted when a new diagnosis of psychosis was followed by an antipsychotic prescription within 60 days.¹

Among 110,923 patients taking methylphenidate matched with 110,923 taking amphetamine, there were 343 episodes, or 2.4 per 1,000 person-years: 106 (0.10%) in the methylphenidate group and 237 (0.21%) in the amphetamine group.¹

In a pooled analysis of short-term, placebo-controlled studies of stimulants, psychotic or manic symptoms occurred in approximately 0.1% of stimulant-treated patients and 0% of placebo-treated patients, according to the FDA labels.^{2, 4, 5}

Amphetamine carried a higher rate than methylphenidate

The hazard ratio for psychosis with amphetamine compared with methylphenidate was 1.65 (95% CI, 1.31 to 2.09).¹ The study compared two medications and had no unmedicated comparison group, so it can't show whether either drug increased risk over no treatment.

A Swedish registry study compared each person's own rate of psychotic events before and after starting methylphenidate. Among 23,898 people who started methylphenidate at ages 12 to 30, the rate in the 12 weeks after starting was similar to the rate in the 12 weeks before, with an incidence rate ratio of 1.04 (95% CI, 0.80 to 1.34) in those without a history of psychosis and 0.95 (0.69 to 1.30) in those with one.⁶

The authors found no evidence that starting methylphenidate increases the risk of psychotic events, including in people with a history of psychosis.⁶ That study included no amphetamine data.

Higher amphetamine doses were associated with higher odds of psychosis or mania

A 2024 case-control study compared 1,374 patients ages 16 to 35 hospitalized at McLean Hospital for new-onset psychosis or mania with 2,748 patients hospitalized for other psychiatric reasons, most commonly depression or anxiety. The outcome combined psychosis and mania, and the abstract doesn't report them separately.⁷

Past-month prescription amphetamine use was associated with higher odds of psychosis or mania compared with no use (adjusted odds ratio 2.68; 95% CI, 1.90 to 3.77). Past-month methylphenidate use was not associated with increased odds (adjusted odds ratio 0.91; 95% CI, 0.54 to 1.55).⁷

The authors observed a dose-response relationship. High doses, defined as more than 30 mg of dextroamphetamine equivalents, were associated with 5.28-fold increased odds of psychosis or mania. The abstract gives no confidence interval for that figure and no conversion to milligrams of a specific product, so it can't be read as an Adderall dose.⁷ Dose decisions are made with the prescriber.

These are odds from hospitalized patients, and they don't give anyone's absolute risk. The authors noted that using hospitalized controls leads to selection bias, and they recommended caution when prescribing high doses of amphetamines, with regular screening for symptoms of psychosis or mania.⁷

What the FDA labels say

The labels for Adderall XR, Vyvanse, and Concerta carry the same warning: stimulants, at the recommended dosage, may cause psychotic or manic symptoms, such as hallucinations, delusional thinking, or mania, in patients without a prior history of psychotic illness or mania.^{2, 3, 4} The labels also state that stimulants may exacerbate behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.^{2, 4, 5}

The labels use the same class wording for amphetamine and methylphenidate and give no dose threshold. Their instruction to prescribers is that if such symptoms occur, discontinuing the medication should be considered.^{2, 3, 4} The Adderall XR label also notes that psychosis has been observed with stimulant abuse and misuse.²

What to do if symptoms appear

Someone who develops hallucinations, delusional thinking, or mania on Adderall, Vyvanse, Ritalin, or Concerta should contact the prescriber right away or go to urgent or emergency care. The prescriber decides whether to stop, lower, or change the medication and what evaluation is needed.

None of the three abstracts reports how long the psychosis lasted, whether it resolved after the stimulant was stopped, or how many patients were later diagnosed with schizophrenia. I've written separately about schizophrenia and psychosis treatment.

Limitations of the evidence

This evidence has limitations. First, none of the three studies is a randomized trial, and the 2019 cohort counted only episodes that led to an antipsychotic prescription in commercially insured patients 13 to 25 years old. Second, the dose finding combines psychosis with mania, comes from one hospital, and has no confidence interval in the abstract. Nevertheless, the absolute risk in the largest study was low, and the association with amphetamine and with higher doses supports asking about psychotic and manic symptoms at follow-up visits.

In a crisis: call or text 988, or go to the nearest emergency department. A first episode of psychosis belongs in a hospital-based or coordinated specialty care program.

I start and manage clozapine in an outpatient practice in Chelsea, Manhattan. Details are on the schizophrenia care in NYC page. Clozapine should not be stopped, skipped, or restarted without the prescriber. This page is general information and does not replace an evaluation.

Related: Schizophrenia and psychosis treatment guide · When to start clozapine · Clozapine blood tests after the REMS ended · Clozapine side effects · Missed clozapine doses · Clozapine and suicide risk · Cannabis and psychosis · Schizoaffective vs schizophrenia · Cobenfy vs clozapine · Postpartum psychosis · Injections vs pills · Drug-induced psychosis · Clozapine levels · CBT for psychosis · Clozapine myocarditis · Cannabis after psychosis · Clozapine constipation · Work and school · Clozapine drooling · Early signs in teens · Clozapine weight gain · Genetic and family risk · Who can prescribe clozapine · Schizophrenia and violence · Clozapine in teenagers · Sleepiness, bedwetting, heart rate · When clozapine isn't enough · Clozapine interactions · Benign ethnic neutropenia · Clozapine off-label uses · Starting clozapine · Clozapine and pneumonia · Clozapine seizures · Clozapine in pregnancy · Clozapine rechallenge · Relative refuses treatment · Late-onset schizophrenia · Negative symptoms · First-episode psychosis · Tardive dyskinesia · Stopping antipsychotics · Schizophrenia life expectancy · Key clozapine studies